Dr. Tilly Discusses Study of POLA-R-CHP in DLBCL

Video

Herve Tilly, MD, PhD, Centre Henri Becquerel, discusses a study of polatuzumab vedotin combined with rituximab (Rituxan), cyclophosphamide, doxorubicin and prednisone (PLOA-R-CHP) in patients with previously untreated diffuse large B-cell lymphoma.

Herve Tilly, MD, PhD, Centre Henri Becquerel, discusses a study of polatuzumab vedotin combined with rituximab (Rituxan), cyclophosphamide, doxorubicin and prednisone (PLOA-R-CHP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Related Content
FDA

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024
Article
Matthew Lunning, DO, FACP

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

December 21st 2023
Podcast
Hung Chang, MD, professor, hematology, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine

Nanatinostat With Valganciclovir Produces Positive Topline Data in EBV+ PTCL

April 15th 2024
Article
Matthew Lunning, DO, FACP

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

October 30th 2023
Podcast
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024
Article
Helen Knight, director of medicines evaluation at NICE

NICE Recommends Tisagenlecleucel for Pediatric R/R B-ALL

April 11th 2024
Article